ALK and cancer: To further investigate the additive effect of SMYD2 inhibition on an ALK inhibitor, we treated H2228 and H3122 cells with one or a combination of crizotinib (ALK inhibitor) and LLY‐507 at their IC50 concentration, and found that the combination of these two compounds additively suppressed the growth of the two cancer cell lines with EML4‐ALK fused protein (Fig. 4c,d).